

PRESS RELEASE**STALLERGENES EXPANDS LATIN AMERICAN PRESENCE
WITH ACQUISITION OF ALERGO PHARMA S.R.L. IN ARGENTINA**

Antony (France), 21 July 2014 – STALLERGENES, a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, announced today the acquisition of the entire share capital of ALERGO PHARMA S.R.L., an Argentinean allergen immunotherapy (AIT) company.

The aim of the acquisition is to combine two complementary dedicated allergen immunotherapy companies, working together to provide a more comprehensive and broader range of diagnosis and treatment solutions to patients suffering from allergic respiratory diseases.

This acquisition establishes STALLERGENES among the top allergen immunotherapy pharmaceutical companies in Latin America further broadening STALLERGENES' geographic presence across the region.

"With its excellent market knowledge, an extensive distribution network and long standing relationships with allergy specialists, ALERGO PHARMA is the leader in the AIT market in Argentina," said Christian Chavy, Chief Executive Officer of STALLERGENES. "This acquisition will significantly enhance STALLERGENES' footprint in Latin America, and is consistent with our long-term strategy and commitment to fast-growing markets."

The terms of the transaction are not disclosed.

ABOUT RESPIRATORY ALLERGIES IN ARGENTINA

The prevalence of allergic rhinitis in Argentina is estimated at between 20% and 30% of the population.

The Argentinean market offers substantial potential for the development of allergen immunotherapy: 8.5 million people are sensitized and the most prevalent allergen is house dust mites. Each year, 2.3 million people are diagnosed with allergy symptoms.

Today, only 150,000 allergy sufferers are treated with allergen immunotherapy. There is therefore a strong need for innovative standardized allergen immunotherapy treatments.

ABOUT STALLERGENES

STALLERGENES is a global healthcare company specialized in the diagnosis and treatment of allergies. For more than 50 years, it has been continuously expanding the existing frontiers of science in order to provide allergy patients with more effective long lasting therapeutic options. Thanks to its innovation strategy, fueled by investments amounting to around 20% of total annual revenues as well as external partnerships, STALLERGENES is able to provide targeted allergen immunotherapy-based allergy solutions that significantly improve the lives of allergy patients around the world.

STALLERGENES operates in 20 countries and employs over 1,000 people. In 2013, the Company generated total revenues of €248 million, and more than 500,000 patients were treated with STALLERGENES products.

Euronext Paris (Compartment B)
CAC small
ISIN: FR0000065674
Reuters: GEN.PA
Bloomberg: GEN.FP



Additional information is available at <http://www.stallergenes.com>

ABOUT ALERGO PHARMA S.R.L.

ALERGO PHARMA is a leading developer and provider of allergen immunotherapy products in the Argentinean market. Fully devoted to allergen immunotherapy, it offers a full range of products recognized for the quality of its allergenic extracts and a continuous supply to the allergy market. ALERGO PHARMA was founded in 1992 and is located in Buenos Aires, Argentina.

Forward-looking statements related to Stallergenes

This press release may contain forward-looking statements, including forecasts of future revenue and operating profit as well as expected business-related events. Such statements are based upon the current beliefs and expectations of Stallergenes' management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, changes in competitive factors and reliance on suppliers. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Contacts:

Christian Chavy, Chief Executive Officer
Tel. +33 1 55 59 20 04

Investor and analyst relations

Peter Bühler
Chief Financial Officer
Phone: +33 1 55 59 20 95
Email: investorrelations@stallergenes.com

Media Relations

Lise Lemonnier
Senior Communication & Public Affairs Director
Phone: + 33 1 55 59 20 96
Email: llemonnier@stallergenes.com

Investor and press relations agency

FTI Consulting – Analyst and investor contact
Stephan Dubosq
Phone: +33 1 47 03 68 16
Email: stephan.dubosq@fticonsulting.com

FTI Consulting – Press contact
Jeanne Bariller
Phone: +33 1 47 03 68 63
Email: jeanne.bariller@fticonsulting.com